Patients with type 2 diabetes who received sodium-glucose cotransporter-2 inhibitors had a lower risk for rheumatic disease ...

The results suggest that dipeptidyl peptidase-4 (DDP-4) inhibitors, which are widely prescribed in Germany, are not a cost-effective option despite lower drug pricing compared with empagliflozin.

Adding a sodium-glucose co-transporter 2 (SGLT2) inhibitor dominated switching to a glucagon-like peptide 1 receptor agonist over the lifetimes of patients with type 2 diabetes not at glycated ...

Patients with type 2 diabetes treated with sodium-glucose cotransporter-2 (SGLT-2) inhibitors have a significantly lower risk of developing dementia and Alzheimer's disease than those receiving ...

Across a broad swath of patients, short-term use of a sodium-glucose cotransporter 2 (SGLT2) inhibitor appears to reduce the risk of major adverse cardiovascular events, most notably cardiovascular ...

GLP-1RAs and DPP-4is are associated with a higher risk for biliary disease than SGLT2is among individuals with type 2 diabetes.

Ling Li, Sheyu Li, Ke Deng, Jiali Liu, Per Olav Vandvik, Pujing Zhao, Longhao Zhang, Jiantong Shen, Malgorzata M Bala, Zahra N Sohani, Evelyn Wong, Jason W Busse, Shanil Ebrahim, German Malaga, Lorena ...

CSPC Pharmaceutical Group Ltd. on Jan. 13 gained the National Medical Products Administration’s approval of Shanzeping (prusogliptin tablets; DBPR-108) as a novel oral dipeptidyl peptidase-IV (DPP-4) ...

Researchers found that the rate difference of depression was 3.48 per 1000 person-years between GLP-1 RA users and SGLT-2i users. HealthDay News — For older adults with type 2 diabetes (T2D), use of ...

Use of sodium-glucose cotransporter-2 (SGLT2) inhibitors does not appear to raise the risk for fractures in older adults, new research suggests. The data come from a nationwide propensity ...